AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition
AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition Nov 10 (Reuters) - AstraZeneca AZN.L has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target company said on Tuesday.
Financial terms of the deal were not disclosed
The acquisition follows a three-year exclusive research collaboration between the companies
The deal brings the US-based company's proprietary platform - which engineers and assembles bacterial vaccine components in a single process - under AstraZeneca's umbrella, boosting the Anglo-Swedish drugmaker's vaccine efforts
"Omniose's bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections," said Benjamin Moutier, AstraZeneca's senior vice president of infectious disease
Despite a diverse drug portfolio, AstraZeneca's on-market vaccine offerings are limited, and its CEO is refocusing on growth, with over 180 pipeline projects underpinning long-term ambitions
AstraZeneca discontinued its Covid-19 vaccine in 2024, but now offers Beyfortus for respiratory syncytial virus infections and FluMist for influenza
It is also exploring the development of cancer vaccines
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Vijay Kishore)
((RaechelThankam.Job@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)